within Pharmacolibrary.Drugs.N_NervousSystem.N01A_AnestheticsGeneral.N01AH06_Remifentanil;

model Remifentanil
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_3C(
    weight = 70,
    F = 1,
    Cl = 4.833333333333333e-05,
    adminDuration = 600,
    adminMass = 1 / 1000000,
    adminCount = 1,
    Vd = 0.00022,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Remifentanil</td></tr><tr><td>ATC code:</td><td>N01AH06</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>3</td></tr>
    <tr><td>dosage:</td><td>1</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.22</td><td>L</td></tr>
    <tr><td>clearance:</td><td>2.9</td><td>L/min</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Remifentanil is an ultra-short-acting synthetic opioid analgesic approved for use as an adjunct to anesthesia during surgery or for sedation in intensive care settings. It is administered intravenously due to its rapid hydrolysis by nonspecific blood and tissue esterases, which gives it a very short context-sensitive half-life. Remifentanil is widely used in clinical practice today for its predictable, rapid onset and offset.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers administered intravenous remifentanil (aged 19–53 years, both sexes).</p><h4>References</h4><ol><li><p>Ziesenitz, VC, et al., &amp; van den Anker, JN (2018). Pharmacokinetics of Fentanyl and Its Derivatives in Children: A Comprehensive Review. <i>Clinical pharmacokinetics</i> 57(2) 125–149. DOI:<a href=\"https://doi.org/10.1007/s40262-017-0569-6\">10.1007/s40262-017-0569-6</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/28688027/\">https://pubmed.ncbi.nlm.nih.gov/28688027</a></p></li><li><p>Imaizumi, T, et al., &amp; Murakawa, M (2017). Population pharmacokinetics of intravenous acetaminophen in Japanese patients undergoing elective surgery. <i>Journal of anesthesia</i> 31(3) 380–388. DOI:<a href=\"https://doi.org/10.1007/s00540-017-2358-7\">10.1007/s00540-017-2358-7</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/28432468/\">https://pubmed.ncbi.nlm.nih.gov/28432468</a></p></li><li><p>Kamata, M, &amp; Tobias, JD (2016). Remifentanil: applications in neonates. <i>Journal of anesthesia</i> 30(3) 449–460. DOI:<a href=\"https://doi.org/10.1007/s00540-015-2134-5\">10.1007/s00540-015-2134-5</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26758072/\">https://pubmed.ncbi.nlm.nih.gov/26758072</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.N.N01AH06 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Remifentanil;
